About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Japan Stocks: Earnings & Guidance Updates After Trading Hours

Stock Price May 15, 4:00 pm JST
Total:
0
Earnings Highlights
PER
PBR
9561 TSE Growth
GLAD CUBE, Jan-Mar (1Q) Ordinary Profit Loss Narrows 832 7.01B
0
ー%
9.56 ー % Mid
9553 TSE Growth
MicroAd, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 24% Increase 331 9.2B
0
ー%
300.9 2.68 ー % Mid
9246 TSE Growth
ProjectHoldings, Jan-Mar (1Q) Ordinary Profit Turns to Profit 1,369 8.04B
-29
-2.1%
3.35 ー % Slightly Low
9218 TSE Growth
Mental Health Tech, Jan-Mar (1Q) Ordinary Profit Turns to Profit 777 8.06B
+11
+1.44%
13.1 6.87 ー % Mid
9162 TSE Growth
Bleach Inc, Jul-Mar (Cumulative 3Q) Ordinary Profit Turns to Profit, Jan-Mar Ordinary Profit Turns to Profit 346 8.82B
+10
+2.98%
0.93 ー % Mid
8938 TSE Growth
GLOME Holdings, Returning to Profitability This Year 698 6.32B
+10
+1.45%
137.4 0.82 0.29 % Mid
7707 TSE Growth
Precision System Science, The Current Fiscal Year Net Income Loss Widened in Downward Revision 192 5.31B
-2
-1.0%
1.36 ー % High
7386 TSE Growth
Japan Warranty Support, First Half Ordinary Profit Decreases by 16%, Jan-Mar Ordinary Profit Decreases by 11% 3,345 8.34B
+5
+0.15%
15.9 2.80 ー % Slightly Low
7325 TSE Growth
IRRC, Jul-Mar (Cumulative 3Q) Ordinary Profit Increases by 30%, Jan-Mar Ordinary Profit Increases by 31% 729 6.35B
+5
+0.69%
14.1 1.60 2.74 % Slightly Low
7091 TSE Growth
Living Platform, 30% Increase in Ordinary Profit for The Current Fiscal Year 1,183 5.29B
-8
-0.7%
16.6 2.61 ー % Slightly Low
7082 TSE Growth
Jimoty, Jan-Mar (1Q) Ordinary Profit Decreases by 24% 1,672 8.34B
-47
-2.7%
17.8 5.80 ー % Mid
6597 TSE Growth
HPC SYSTEMS, Jul-Mar (Cumulative 3Q) Ordinary Profit Increases by 35%, Exceeds Full-Year Plan 1,265 5.52B
+53
+4.37%
12.8 2.04 2.06 % Mid
6580 TSE Growth
Writeup, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 2% Increase in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 1.11 yen, This Fiscal Year to Increase Dividend by 2 yen 1,662 9.65B
-6
-0.4%
16.6 2.73 1.20 % Mid
6574 TSE Growth
Convano, 4.3 times Increase in Net Income, Record High for The First Time in Six Years 2,048 8.88B
+29
+1.44%
26.5 5.09 ー % Mid
6554 TSE Growth
SUS, First Half Ordinary Profit Increases by 78%, Jan-Mar Ordinary Profit Increases by 84% 1,016 9.18B
-10
-1.0%
12.4 2.32 3.44 % Mid
6176 TSE Growth
Brangista.inc, First Half Ordinary Profit Increases by 10% 592 8.63B
0
ー%
11.1 1.85 ー % Mid
6094 TSE Growth
FreakOut, The Current Fiscal Year Ordinary Profit Revised Downward to Range from 50 Million Yen to 550 Million Yen 533 9.61B
-10
-1.8%
0.89 ー % Mid
6045 TSE Growth
Rentracks, 14% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Dividend Raised by 1 yen 971 7.74B
-53
-5.2%
10.6 2.13 2.47 % Mid
4892 TSE Growth
Cyfuse Biomedical, Jan-Mar (1Q) Ordinary Profit Loss Narrows 979 8.13B
-20
-2.0%
3.49 ー % Slightly High
4882 TSE Growth
Perseus Proteomics, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed. 431 6.36B
0
ー%
4.70 ー % High
About:
Liquidity
Labels